Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
Persuasive
Early and easy detection of ischemic heart disease

Persuasive addresses the challenge of identifying Stable Angina patients early on, crucial for preventing heart attacks. Currently, without a diagnostic test in general practitioner settings, many referrals to hospitals prove unnecessary. The solution is a simple blood test, leveraging an extracellular vesicle protein signature to distinguish SA patients from those with non-cardiac chest pain. This innovative approach promises to streamline patient management, saving lives and healthcare resources.

Active
🇳🇱 Netherlands
Persuasive
Wavefront
Transforming live-cell imaging using AI technology

Wavefront is revolutionizing live-cell imaging with their AI-driven computational microscope, offering a stain-free imaging technique powered by patented quantitative-phase-imaging (QPI) technology. This approach eliminates the need for costly and invasive chemical staining, preserving cell integrity with real-time visualization of cellular structures with precision and detail. Wavefront's innovative solution has transformative potential research across diverse fields, from cancer research to clinical diagnostics.

Active
🇪🇸 Spain
Wavefront
Crainio
Advancing brain health with a non-invasive pressure monitor for traumatic injuries

Crainio pioneers intracranial pressure (ICP) monitoring, for assessing traumatic brain injuries (TBI) without invasive procedures. Traditional methods involve drilling into the skull, posing risks. Crainio's method uses a forehead probe and a technique called photoplethysmography to measure pulse signals. This gives real-time estimates of ICP without invasive procedures. With TBI being a leading cause of death and disability, Crainio's innovation will potentially revolutionize TBI management.

Active
🇬🇧 United Kingdom
Crainio
NeurOdys Therapeutics
Developing treatments to slow or reverse Alzheimer's disease

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

Active
🇳🇱 Netherlands
NeurOdys Therapeutics
Sigilla Medical
Sigilla Medical has developed an implant-free device and procedure that safely closes PFOs with minimal complications, improving patient outcomes.

Sigilla Medical is developing an innovative, implant-free radiofrequency device designed to close PFOs (patent foramen ovale) in stroke-risk patients. PFOs are associated with cryptogenic stroke and migraine, and current treatment involves placing a large metal device that spans the septum of the heart in an otherwise young and healthy patient. Sigilla’s device offers a safer, more efficient alternative by using controlled radiofrequency to seal the PFO without the need for implants. This less-invasive approach reduces procedural risk and adverse cardiac events while leaving options open for future minimally invasive procedures.

Active
🇮🇪 Ireland
Sigilla Medical
Nilocas
A cardiac device for the detection of coronary artery disease

Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Active
🇬🇧 United Kingdom
Nilocas
MindAffect
Building the next generation of hearing & vision diagnostics

MindAffect is redefining what’s possible in diagnostics. By harnessing Brain-Computer Interface technology and AI, we can “read” how the brain reacts to sound and visual stimuli—objectively, in real time, and without requiring a single response from the patient. At the core is our patented and clinically validated Rapid CAEP® technology, which captures the brain’s automatic reactions. This breakthrough allows clinicians to diagnose patients who would otherwise be difficult or impossible to test—such as infants, seniors, and individuals with disabilities. In a world where over two billion people are underserved by current diagnostic methods, this changes everything. Our first product, Sofi, is the world’s fastest objective hearing diagnostic system, delivering accurate hearing thresholds in minutes. Sofi has been validated in leading hospitals, championed by key opinion leaders across the audiology community, and recognized globally—winning the Innovation Award at the World Congress of Audiology

Active
🇳🇱 Netherlands
MindAffect
Axial
Bone repair system reduces pain after surgery and brings better recovery

Axial Orthopaedics Inc. revolutionizes trauma treatment with their innovative intramedullary nailing system. Current systems often lead to bone misalignment and joint pain, blocking post-procedural recovery. Axial Orthopaedics's modular system offers greater flexibility in bone alignment and healing. This system not only addresses postoperative pain but also reduces complications. Its intra-operative modularity and rotational capabilities allow surgeons to achieve better fracture fixation and improved outcomes, filling a crucial gap in current technology.

Active
🇺🇸 United States of America
Axial

Our impact

15
Countries active in
€190M+
Raised by NLC ventures
20-25
Ventures built annually
2M+
Patients impacted
40+
Healthcare experts
70+
Active ventures in our portfolio

Explore our 2024 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Lars Olthof
Head of Venture Finance, Venture Investment Director